NeuroNOS Granted FDA Orphan Drug Designation for Phelan-McDermid Syndrome, a Neurodevelopmental Disorder Linked to Autism
April 21, 2025
NeuroNOS Appoints Nobel Prize Laureate, Professor Dan Shechtman, to Scientific Advisory Board
April 15, 2025
NeuroNOS Announces Groundbreaking Research Publication by its CSO Demonstrating Mechanism of Action in Alzheimer’s Disease and Reinforcing Platform’s Strength Across Neurological Disorders
April 1, 2025
NeuroNOS Secures $2.0 Million in Funding to Advance Development of an Innovative Autism Therapy
March 24, 2025
NeuroNOS Appoints Nobel Laureate, Roger D. Kornberg, to Scientific Advisory Board
November 26, 2024
Beyond Air® Announces Positive Preclinical Data on Role of Nitric Oxide in Autism Spectrum Disorder (ASD)
August 07, 2023
Beyond Air® Licenses Commercial Rights to Selective Neuronal Nitric Oxide Synthase (nNOS) Inhibitors for the Treatment of Autism Spectrum Disorder from Hebrew University of Jerusalem
June 15, 2023
The NO Answer for Autism Spectrum Disorder
M. K. Tripathi, S. K. Ojha, M. Kartawy, W. Hamoudi, A. Choudhary, S. Stern, A. Aran, H. Amal (2023), June 2023
The Role of Thioredoxin System in Shank3 Mouse Model of Autism
Bazbaz W. et al. Journal of Molecular Neuroscience, 2024
Effects of extended-release 7-nitroindazole gel formulation treatment on the behavior of Shank3 mouse model of autism
Amal H. et al. (2023), September 2023
A cross-talk between nitric oxide and the glutamatergic system in a Shank3 mouse model of autism
Hamoudi W. et al. Free Radical Biology and Medicine, 2022
Arsenic alters nitric oxide signaling similar to autism spectrum disorder and Alzheimer's disease-associated mutations
Tripathi M. et al. Translational Psychiatry, 2022
Proteomics of autism and Alzheimer’s mouse models reveal common alterations in mTOR signaling pathway
Mencer S. et al. Translational psychiatry, 2021
*All publications were published by Prof. Amal's academic research staff